View Item 

Show simple item record

Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer

dc.contributor.authorUdager, Aaron M.en_US
dc.contributor.authorShi, Yangen_US
dc.contributor.authorTomlins, Scott A.en_US
dc.contributor.authorAlva, Ajjaien_US
dc.contributor.authorSiddiqui, Javeden_US
dc.contributor.authorCao, Xuhongen_US
dc.contributor.authorPienta, Kenneth J.en_US
dc.contributor.authorJiang, Huien_US
dc.contributor.authorChinnaiyan, Arul M.en_US
dc.contributor.authorMehra, Rohiten_US
dc.date.accessioned2014-08-06T16:49:33Z
dc.date.availableWITHHELD_14_MONTHSen_US
dc.date.available2014-08-06T16:49:33Z
dc.date.issued2014-09en_US
dc.identifier.citationUdager, Aaron M.; Shi, Yang; Tomlins, Scott A.; Alva, Ajjai; Siddiqui, Javed; Cao, Xuhong; Pienta, Kenneth J.; Jiang, Hui; Chinnaiyan, Arul M.; Mehra, Rohit (2014). "Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate cancer." The Prostate 74(12): 1199-1208.en_US
dc.identifier.issn0270-4137en_US
dc.identifier.issn1097-0045en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108006
dc.publisherSpringeren_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherFluorescent in Situ Hybridization (FISH)en_US
dc.subject.otherRapid Autopsyen_US
dc.subject.otherAndrogen Receptor (AR)en_US
dc.subject.otherTMPRSS2‐ERGen_US
dc.subject.otherImmunohistochemistry (IHC)en_US
dc.titleFrequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration‐resistant prostate canceren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108006/1/pros22836.pdf
dc.identifier.doi10.1002/pros.22836en_US
dc.identifier.sourceThe Prostateen_US
dc.identifier.citedreferenceRubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000; 6 ( 3 ): 1038 – 1045.en_US
dc.identifier.citedreferenceTomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 ( 5748 ): 644 – 648.en_US
dc.identifier.citedreferenceTomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007; 448 ( 7153 ): 595 – 599.en_US
dc.identifier.citedreferenceKumar‐Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8 ( 7 ): 497 – 511.en_US
dc.identifier.citedreferenceTomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM. Role of the TMPRSS2‐ERG gene fusion in prostate cancer. Neoplasia 2008; 10 ( 2 ): 177 – 188.en_US
dc.identifier.citedreferenceBrenner JC, Chinnaiyan AM, Tomlins SA. ETS fusion genes in prostate cancer. In: Tindall DJ, editor. Prostate cancer: Biochemistry, molecular biology and genetics, protein reviews. New York: Springer; 2013.en_US
dc.identifier.citedreferenceMehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: Molecular evidence for an independent group of diseases. Cancer Res 2007; 67 ( 17 ): 7991 – 7995.en_US
dc.identifier.citedreferenceBarry M, Perner S, Demichelis F, Rubin MA. TMPRSS2‐ERG fusion heterogeneity in multifocal prostate cancer: Clinical and biologic implications. Urology 2007; 70 ( 4 ): 630 – 633.en_US
dc.identifier.citedreferenceMehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20 ( 5 ): 538 – 544.en_US
dc.identifier.citedreferenceMehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Characterization of TMPRSS2‐ETS gene aberrations in androgen‐independent metastatic prostate cancer. Cancer Res 2008; 68 ( 10 ): 3584 – 3590.en_US
dc.identifier.citedreferencePark K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA. Antibody‐based detection of ERG rearrangement‐positive prostate cancer. Neoplasia 2010; 12 ( 7 ): 590 – 598.en_US
dc.identifier.citedreferenceGopalan A, Leversha MA, Dudas ME, Maschino AC, Chang J, Al‐Ahmadie HA, Chen YB, Tickoo SK, Reuter VE, Fine SW. TMPRSS2‐ERG rearrangement in dominant anterior prostatic tumours: Incidence and correlation with ERG immunohistochemistry. Histopathology 2013; 63 ( 2 ): 279 – 286.en_US
dc.identifier.citedreferenceTeng LH, Wang C, Begin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration‐resistant prostate cancer compared to localized disease. Urology 2013; 82 ( 2 ): 394 – 399.en_US
dc.identifier.citedreferenceGsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C. ERG rearrangement and protein expression in the progression to castration‐resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17 ( 2 ): 126 – 131.en_US
dc.identifier.citedreferenceSchelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez‐Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Comperat E, Cheng L. Frequent TMPRSS2‐ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol 2013; 44 ( 10 ): 2227 – 2233.en_US
dc.identifier.citedreferenceLotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A, Hicks JL, Meeker AK, Bieberich CJ, De Marzo AM, Epstein JI, Netto GJ. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24 ( 6 ): 820 – 828.en_US
dc.identifier.citedreferenceEmbuscado EE, Laheru D, Ricci F, Yun KJ, de Boom Witzel S, Seigel A, Flickinger K, Hidalgo M, Bova GS, Iacobuzio‐Donahue CA. Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005; 4 ( 5 ): 548 – 554.en_US
dc.identifier.citedreferenceShah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen‐independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64 ( 24 ): 9209 – 9216.en_US
dc.identifier.citedreferenceMehra R, Kumar‐Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res 2011; 17 ( 12 ): 3924 – 3932.en_US
dc.identifier.citedreferenceGrasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. The mutational landscape of lethal castration‐resistant prostate cancer. Nature 2012; 487 ( 7406 ): 239 – 243.en_US
dc.identifier.citedreferenceSinghi AD, Cimino‐Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol 2012; 25 ( 3 ): 378 – 387.en_US
dc.identifier.citedreferenceLi Z, Chen CJ, Wang JK, Hsia E, Li W, Squires J, Sun Y, Huang J. Neuroendocrine differentiation of prostate cancer. Asian J Androl 2013; 15 ( 3 ): 328 – 332.en_US
dc.identifier.citedreferenceHuang J, Yao JL, di Sant'Agnese PA, Yang Q, Bourne PA, Na Y. Immunohistochemical characterization of neuroendocrine cells in prostate cancer. Prostate 2006; 66 ( 13 ): 1399 – 1406.en_US
dc.identifier.citedreferenceSlovin SF. Neuroendocrine differentiation in prostate cancer: A sheep in wolf's clothing ? Nat Clin Pract Urol 2006; 3 ( 3 ): 138 – 144.en_US
dc.identifier.citedreferenceBeltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1 ( 6 ): 487 – 495.en_US
dc.identifier.citedreferenceLapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, Fazli L, Hurtado‐Coll A, Jones EC, Hach F, Hormozdiari F, Hajirasouliha I, Boutros PC, Bristow RG, Zhao Y, Marra MA, Fanjul A, Maher CA, Chinnaiyan AM, Rubin MA, Beltran H, Sahinalp SC, Gleave ME, Volik SV, Collins CC. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol 2012; 227 ( 3 ): 286 – 297.en_US
dc.identifier.citedreferenceUdager AM, Alva A, Mehra R. Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution. Cancer J 2014; 20 ( 1 ): 29 – 42.en_US
dc.identifier.citedreferenceRoychowdhury S, Chinnaiyan AM. Advancing precision medicine for prostate cancer through genomics. J Clin Oncol 2013; 31 ( 15 ): 1866 – 1873.en_US
dc.identifier.citedreferenceBrenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba‐Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic rationale for inhibition of poly(ADP‐ribose) polymerase in ETS gene fusion‐positive prostate cancer. Cancer Cell 2011; 19 ( 5 ): 664 – 678.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pros22836.pdf
Size:
4.210MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.